Global footprint SCHOTT Pharma operates 16 manufacturing sites across Europe, the Americas and Asia, with ongoing expansions such as Lebanon, Pennsylvania, enabling regional supply chains and multi-market access for cross-sell of containment and delivery systems to top injectable manufacturers.

Biologics push Recent launches like cartriQ BioPure and ready-to-use polymer cartridges signal a strategic move into biologics and sensitive biologic drugs, creating sales opportunities with biopharma and CDMOs needing specialized containment and delivery solutions for injections.

Customer scale With over 1,800 customers including the top 30 injectable manufacturers and substantial revenue, SCHOTT Pharma offers a large addressable market for expanding existing platforms, premium containment options, and customized packaging across regions.

Innovation and partnerships A strong in-house IP portfolio, a Swiss R&D center, and active partnerships with Halozyme and Elektrofi indicate a collaborative approach to enabling advanced Drug Delivery Technologies, presenting opportunities for co-development and integrated solutions.

Sustainability edge Climate-neutral by 2030 and ESG-aligned priorities provide a differentiator for selling sustainable materials and packaging, regulatory compliance benefits, and supply-chain resilience to pharma customers prioritizing sustainability.